BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO
Portfolio Pulse from Charles Gross
BioNTech and OncoC4 announced positive preliminary data from their ongoing Phase 1/2 trial for BNT316/ONC-392, an anti-CTLA-4 antibody candidate, in patients with metastatic, PD-(L)1-resistant non-small cell lung cancer. The results show encouraging clinical anti-tumor activity and a manageable safety profile.
June 02, 2023 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech's stock may be positively impacted by the encouraging preliminary data from the ongoing Phase 1/2 trial for BNT316/ONC-392 in hard-to-treat NSCLC patients.
The positive preliminary data from the ongoing Phase 1/2 trial for BNT316/ONC-392 in hard-to-treat NSCLC patients indicates potential for the antibody candidate to become a successful treatment option. This could lead to increased revenue for BioNTech and positively impact its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100